Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 83
- Registration Number
- NCT04584112
- Locations
- 🇺🇸
Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States
🇦🇺Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia
🇧🇷Hospital Sírio-Libanês, Sao Paulo, SP, Brazil
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 59
- Registration Number
- NCT04580121
- Locations
- 🇮🇹
Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇩🇰Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
- Conditions
- Interventions
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 303
- Registration Number
- NCT04576455
- Locations
- 🇵🇱
Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej, Bialystok, Poland
🇨🇳Fudan University Shanghai Cancer Center, Shanghai City, China
🇨🇳Hubei Cancer Hospital, Wuhan, China
Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 251
- Registration Number
- NCT04567303
- Locations
- 🇺🇸
The Retina Care Center, Baltimore, Maryland, United States
🇺🇸Mid Atlantic Retina - Wills Eye Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Tennessee Retina PC., Nashville, Tennessee, United States
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 225
- Registration Number
- NCT04557150
- Locations
- 🇦🇺
Peter MacCallum Cancer Center, North Melbourne, Victoria, Australia
🇧🇪UZ Gent, Gent, Belgium
🇩🇰Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 665
- Registration Number
- NCT04552899
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇺🇸San Marcus Research Clinic Inc., Miami, Florida, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 769
- Registration Number
- NCT04548999
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸Massachusetts General Hospital., Boston, Massachusetts, United States
🇵🇱Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Bada? Klinicznych, Plewiska, Poland
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT04551352
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 992
- Registration Number
- NCT04546009
- Locations
- 🇺🇸
Long Beach Memorial Medical Center, Fountain Valley, California, United States
🇺🇸Orange Coast Memorial Medical Center, Fountain Valley, California, United States
🇺🇸Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 760
- Registration Number
- NCT04543617
- Locations
- 🇺🇸
MD Anderson Cancer Center; Oncology, Houston, Texas, United States
🇿🇦Limpopo Cancer Research Institute, Polokwane, South Africa
🇺🇸Compassionate Cancer Care Medical Group, Inc, Corona, California, United States